Lisocabtagene Maraleucel Achieves High Responses and Durable 3-Year Remissions for R/R Follicular Lymphoma: TRANSCEND FL
According to results from the phase 3 TRANSCEND FL study, presented at the 2025 ASH Annual Meeting & Exposition by Sairah Ahmed, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, a single infusion of lisocabtagene maraleucel (liso-cel) produced durable, high response rates among patients with relapsed/refractory (R/R) follicular lymphoma (FL) after at least 3 prior lines of therapy.
Dr Ahmed concluded, “in terms of the update for the 3-year outcomes for liso-cel in follicular lymphoma, we continue to see excellent overall response rates, complete response rates, and very good duration of response for this population of patients even enriched for high-risk patients.”
Source:
Ahmed S, Garcia-Sancho AM, Reguera JL, et al. Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL. Dec 6-9, 2025; Orlando, FL. Abstract: 467
